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TerpeneEpilepsy affects about 40 million people worldwide. Many drugs block seizures, but have little effect in
preventing or curing this disease. So the search for new drugs for epilepsy treatment using animal models
prior to testing in humans is important. Increasingly pharmaceutical industries invest in the Research & Drug De-
velopment area to seek safe and effective new therapeutic alternatives to the currently available epilepsy treat-
ment. In this perspective, natural compounds have been investigated in epilepsy models, particularly the
monoterpenes obtained from medicinal plants. In our study we investigated the effects of cyane-carvone (CC),
a synthetic substance prepared from natural a monoterpene, carvone, against pilocarpine- (PILO),
pentylenetetrazole- (PTZ) and picrotoxine (PTX)-induced seizures in mice after acute treatment with repeated
oral doses (CC 25, 50 and 75 mg/kg) for 14 days. CC in all doses tested showed increase in latency to ﬁrst seizure,
decrease in percentages of seizuring animals as well as reduction percentages of dead animals (p b 0.05) in PILO,
PTZ and PTX groups when compared with vehicle. However, these effects were not reversed by ﬂumazenil, ben-
zodiazepine (BZD) antagonist used to investigate the CC action mechanism. Our results suggest that acute treat-
ment with CC at the doses tested can exert anticonvulsant effects in PILO, PTZ and PTX epilepsy models. In
addition, our data suggest that CC could act in an allosteric site of GABAA, which would be different from the
site inwhich BDZ acts, since ﬂumazenil was not able to reverse any of CC effects on themodulation of seizure pa-
rameters relatedwith epilepsymodels investigated. New studies should be conducted to investigate CC effects in
other neurotransmitter systems. Nevertheless, our study reinforces the hypothesis that CC could be used, after
further research, as a new pharmaceutical formulation and a promising alternative for epilepsy treatment,
since it showed anticonvulsant effects.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Epilepsy is a disease that affects about 40 million people worldwide
(Njamnshi et al., 2010). Many drugs block seizures, but have little effect
in preventing or curing this disease, and the search for newdrugs for ep-
ilepsy treatment using animal models prior to testing in humans is im-
portant (Loeb, 2011). Among the drugs that act on the central nervous
system, altering cognition and psychomotor activity, benzodiazepines
can be highlighted for their therapeutic effects like sedation, hypnosis
andmuscle relaxation, but have high rates of tolerance and dependenceNeuroquímica Experimental,
istro Petrônio Portella, Curso de
Tel.: +55 86 3215 5870.
).(Telles Filho et al., 2011). Given this information, it is plausible to inves-
tigate new compounds with anticonvulsant properties devoid of these
side effects. In this regard, various studies have investigated the anticon-
vulsant effects of natural compounds, as well as synthetic compounds
derived from essential oils isolated from monoterpenes.
Carvone (p-mentha-6,8-dien-2-one) is a monoterpene ketone
found as the main active component of various essential oils. It
is obtained by distillation and occurs naturally as the enantiomers
(+)- and (−)-carvone (Gonçalves et al., 2010). Lippia alba (Mill.) N.E.
Brown (Verbenaceae) is widely used in different regions of Central
and South America as a tranquilizer and (R)-(-)-carvone is the main
constituent of this plant (Hatano et al., 2012). (-)-Carvone is also
found in spearmint (Mentha spicata var. crispa) essential oil, which is
widely used as an odor andﬂavor additive (Souza et al., 2013). In studies
conducted by De Sousa et al. (2007), (+)-carvone signiﬁcantly
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zures in mice. This information reinforces the need to investigate the
effects of cyane-carvone, a carvone derivative, obtained from essential
oils in epilepsy models as a new therapeutic approach to epilepsy
treatment.
In addition, cyane-carvone showed a potential antioxidant activity
in vitro, by its capacity to inhibit hydroxyl radical formation inhibition
and removenitric oxide, and also by preventing thiobarbituric acid reac-
tive substances (TBARS) production (Costa et al., 2012c). Costa et al.
(2012a) have shown that cyane-carvone possesses anticonvulsant ac-
tivity probably due to the modulation of cholinergic system and reduc-
tion of neuronal oxidative stress in vivo mainly through free radical
scavenging capacity. Their study showed that cyane-carvone may be
helpful to produce neuronal protection and may be considered as a po-
tential natural anticonvulsant. However, additional studies should be
conducted to determine its action mechanism, which further reinforces
the need for realize this study.
Cyane-carvone was used at doses up to 2000 mg/kg without
causing any death of mice (Costa et al., 2012b) and presented a larger
therapeutic window than diazepam, whose lethal dose 50% (LD50) is
of 700 mg/kg (Clark, 1978), suggesting that cyane-carvone could be
used safely and effectively in epilepsy models. Thus, in this research,
the potential pharmacological activity of cyane-carvone was studied
in experimental models to elucidate its anticonvulsant effects in
mice. This workwas performed to investigate the cyane-carvone effects
on pilocarpine- (PILO), pentylenetetrazole- (PTZ) and picrotoxine
(PTX)-induced seizure models as well as its anticonvulsant action
mechanism in mice after acute treatment with repeated oral doses for
14 days.
2. Material and methods
2.1. Cyane-carvone preparation
The compound cyane-carvone (Fig. 1) was prepared in our laborato-
ry as previously described (De Sousa et al., 2010). The purity of cyane-
carvone was 90%. The substance is insoluble in water and soluble in
chloroform.
2.2. Drugs and reagents
Pilocarpine (PILO), pentylenetetrazole (PTZ), picrotoxin (PTX),
polyoxyethylene-sorbitan monolated (Tween 80) and ﬂumazenil were
purchased from Sigma (USA) and diazepam (DZP) from Cristália
(Brazil). Agents were orally (p.o., by gavage) or intraperitoneally (i.p.)
administered at a dose volume of 0.1 mL/10 g.
2.3. Animal and experimental protocol
Swiss male miceMus musculus (25–30 g; 2-month-old) were used.
Animals were housed in cages with free access to food and water and
were kept under standard light–dark cycle (lights on at 07:00 a.m.)
and controlled temperature (25 ± 2 °C). Animals were tested duringFig. 1. Chemical structure of cyane-carvone [(1S,2S,5R)-5-isopropenyl-2-methyl-3-oxo-
cyclohexanocarbonitrile] (Costa et al., 2012c).the light period and observed in a closed roomwith controlled temper-
ature (25±2 °C). Protocol and procedureswere approved by the Ethics
Committee in Animal Experimentation of UFPI (CEEA/UFPI Number
016/2011). The experiments were performed according to the Guide
for Care and Use of Laboratory of US Department of Health and
Human Services, Washington, DC (1985).
To investigate the cyane-carvone effects, the animals received acute
treatment at repeated oral doses for 14 days. Vehicle group was treated
with 0.05% Tween 80 dissolved in 0.9% saline (0.1 mL/kg of weight/day,
p.o., n = 12; negative control). CC 25, CC 50 and CC 75 groups were
treated with cyane-carvone in emulsiﬁed in 0.05% Tween 80 dissolved
in 0.9% saline at doses of 25, 50 and 75 mg/kg (o.r., n=12), respective-
ly. DZP group was treated with diazepam (5 mg/kg, p.o., n= 12; posi-
tive control) emulsiﬁed vehicle.
In turn, to clarify the cyane-carvone actionmechanism, other groups
were treated with ﬂumazenil, DZP and CC at a dose of 75 mg/kg and
associations. The FLU group was treated with ﬂumazenil (5 mg/kg,
p.o., n = 12) emulsiﬁed vehicle. The DZP + FLU group (n = 12) was
pretreated with ﬂumazenil (5 mg/kg, o.r.) and, after 15 min, treated
with diazepam (5 mg/kg, o.r.). The CC 75 + FLU group (n = 12) was
pretreated with ﬂumazenil (5 mg/kg, o.r.) and, after 15 min, treated
with cyane-carvone (75 mg/kg, o.r.).
2.4. Pilocarpine-induced seizure test
This model was developed by Turski et al. (1983). After 30min from
the last dose of CC, all groups received pilocarpine (400 mg/kg, i.p.;
PILO). Direct observation by the researcher was performed for 4 h to
monitor latency to the ﬁrst seizure (tonic–clonic seizures with or
without rearing), the number of animals that seized and death
(Freitas, 2009).
2.5. Pentylenetetrazole-induced seizure test
Pentylenetetrazole (PTZ) was used to induce clonic convulsions
(Smith et al., 2007). After 30min from the last dose of CC, all groups re-
ceived PTZ (60 mg/kg, i.p.) and animals were observed for 4 h to mon-
itor the same parameters of the previous test.
2.6. Picrotoxin-induced seizure test
After 30 min from the last dose of CC, all groups were treated with
picrotoxin (PTX) at dose 8 mg/kg (i.p.). Immediately after the adminis-
tration of the convulsant agent, the animals were observed for 24 h to
monitor the same previous parameters (Lehmann et al., 1988; Bum
et al., 2001).
2.7. Statistical analysis
The datawere shown asmean± standard errormean. For statistical
analysis, latency to the ﬁrst convulsion was examined through analysis
of variance (ANOVA) for multiple comparisons and Student–Newman–
Keuls as post hoc test by GraphPad Prism version 5.00 for Windows
(GraphPad Software, San Diego California, USA). Chi square test was
used to analyse percentage of animals with seizures and mortality
rate. Differences were considered statistically signiﬁcant when p b 0.05.
3. Results
Cyane-carvone effects in PILO-induced seizures in mice are present-
ed in Table 1. CC 25, CC 50 and CC 75 groups showed a signiﬁcant in-
crease in latency to ﬁrst seizure [F(19.9) = 174.8%, F(23.6) = 225.9% and
F(34.6) = 381.0%, respectively; p b 0.05] when compared with the vehi-
cle group, and this effect was not reversed by ﬂumazenil. Percentages of
number of animals with seizure decreased signiﬁcantly in CC 25, CC 50
and CC 75 groups [F(75) = 25%, F(50) = 50% and F(25) = 75%,
Table 1
Effects of acute treatment with cyane-carvone (25, 50 and 75 mg/kg) at repeated oral
doses on PILO-induced seizure test in mice.
Treatments Dose (mg/kg) Latency (s) Seizure (%) Death animals (%)
Vehicle – 7.2 ± 1.1 100 100
DZP 5 27.7 ± 1.4a 16.7b 16.7b
FLU 5 7.4 ± 1.5 100 100
CC 25 19.9 ± 1.0a 75b 75b
50 23.6 ± 0.7a 50b 50b
75 34.6 ± 0.6a,g,h 25b 25b
DZP + FLU 5 + 5 7.2 ± 0.8c 100e 100e
CC + FLU 75 + 5 35.7 ± 1.3d 16.7f 16.7f
Values were shown asmean ± S.E.M. for 8 mice (per group). ap b 0.05 (ANOVA followed
by t-Student–Neuman–Keuls as post hoc test), signiﬁcantly different from vehicle.
bp b 0.01 (χ2 test), signiﬁcantly different from vehicle. cp b 0.001, (ANOVA followed by
t-Student–Neuman–Keuls as post hoc test), signiﬁcantly different from the DZP group.
dp b 0.001 (ANOVA followed by t-Student–Neuman–Keuls as post hoc test), signiﬁcantly
different from the CC 75 group. ep b 0.01 (χ2 test), signiﬁcantly different from the DZP
group. fp b 0.01 (χ2 test), signiﬁcantly different from the CC 75 group. gp b 0.05 (ANOVA
followed by t-Student–Neuman–Keuls as post hoc test), signiﬁcantly different from the
CC 25 group. hp b 0.05 (ANOVA followed by t-Student–Neuman–Keuls as post hoc test),
signiﬁcantly different from the CC 50 group.
Table 3
Effects of acute treatment with cyane-carvone (25, 50 and 75 mg/kg) at repeated oral
doses on PTX-induced seizure test in mice.
Treatments Dose (mg/kg) Latency (s) Seizures (%) Death animals (%)
Vehicle – 485.3 ± 4.8 100 100
DZP 5 1267.9 ± 4.1a 20b 20b
CC 25 378.5 ± 0.6 91.7 91.7
50 531.9 ± 0.4a,c 83.3b 83.3b
75 1003.2 ± 1.8a,c,d 66.7b 66.7b
Values were shown as the mean ± S.E.M. for 8 mice (per group). ap b 0.05 (ANOVA
followed by t-Student–Neuman–Keuls as post hoc test), signiﬁcantly different from vehi-
cle. bp b 0.01 (χ2 test), signiﬁcantly different from vehicle. cp b 0.05 (ANOVA followed
by t-Student–Neuman–Keuls as post hoc test), signiﬁcantly different from the CC 25
group. dp b 0.05 (ANOVA followed by t-Student–Neuman–Keuls as post hoc test), signiﬁ-
cantly different from the CC 50 group.
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ages of number of dead animals decreased signiﬁcantly in CC 25, CC 50
and CC 75 groups [F(75)= 25%, F(50) = 50% and F(25)= 75%, respective-
ly; p b 0.05] when compared with the vehicle group. Flumazenil signif-
icantly reversed the effects of diazepam 5 mg/kg; however, it did not
reverse the effects of cyane-carvone 75 mg/kg on the parameters tested
in PILO-induced seizures.
The evaluation of cyane-carvone effects in PTZ-induced seizures in
mice is shown in Table 2. CC 25, CC 50 and CC 75 groups showed a sig-
niﬁcant increase in latency to ﬁrst seizure [F(99.6) = 33.3%, F(123.8) =
65.8% and F(237.9) = 218.7%, respectively; p b 0.05] when compared
with the vehicle group, and this effect was not reversed by ﬂumazenil.
Percentages of number of animals with seizure decreased signiﬁcantly
in CC 25, CC 50 and CC 75 groups [F(91.7) = 8.3%, F(75) = 25% and
F(58.4)= 41.7%, respectively; p b 0.05] when comparedwith the vehicle
group. Percentages of number of dead animals decreased signiﬁcantly in
CC 25, CC 50 and CC 75 groups [F(91.7) = 8.3%, F(75) = 25% and F(58.4) =
41.7%, respectively; p b 0.05] when compared with the vehicle group.
Similarly to the previous test, ﬂumazenil also signiﬁcantly reversed
the anticonvulsant effects of diazepam 5 mg/kg; however, it did not re-
verse the effects of cyane-carvone 75 mg/kg on the parameters ana-
lyzed in PTZ-induced seizures.
The analyses of cyane-carvone effects in PTX-induced seizures in
mice are shown in Table 3. CC 50 and CC 75 groups showed a signiﬁcantTable 2
Effects of acute treatment with cyane-carvone (25, 50 and 75 mg/kg) at repeated oral
doses on PTZ-induced seizure test in mice.
Treatments Dose (mg/kg) Latency (s) Seizures (%) Death animals (%)
Vehicle – 74.7 ± 1.5 100 100
DZP 5 879.4 ± 0.9a 30b 30b
FLU 5 73.0 ± 2.0 100 100
CC 25 99.6 ± 1.3a 91.7b 91.7b
50 123.8 ± 2.8a 75b 75b
75 237.9 ± 2.2a,g,h 58.4b 58.4b
DZP + FLU 5 + 5 75.0 ± 0.6c 100e 100e
CC + FLU 75 + 5 234.7 ± 2.8d 66.7f 66.7f
Values were shown as the mean ± S.E.M. for 12 mice (per group). ap b 0.05 (ANOVA
followed by t-Student–Neuman–Keuls as post hoc test), signiﬁcantly different from vehi-
cle. bp b 0.01 (χ2 test), signiﬁcantly different from vehicle. cp b 0.001 (ANOVA followed
by t-Student–Neuman–Keuls as post hoc test), signiﬁcantly different from the DZP
group. dp b 0.001 (ANOVA followed by t-Student–Neuman–Keuls as post hoc test), signif-
icantly different from the CC 75 group. ep b 0.01 (χ2 test), signiﬁcantly different from the
DZP group. fp b 0.01 (χ2 test), signiﬁcantly different from the CC 75 group. gp b 0.05
(ANOVA followed by t-Student–Neuman–Keuls as post hoc test), signiﬁcantly different
from the CC 25 group. hp b 0.05 (ANOVA followed by t-Student–Neuman–Keuls as post
hoc test), signiﬁcantly different from the CC 50 group.increase in latency toﬁrst seizure [F(531.9)=9.6% and F(1003.2)= 106.7%,
respectively, p b 0.05] when compared with the vehicle group.
Percentages of number of animals with seizure decreased signiﬁcantly
in CC 50 and CC 75 groups [F(83.3) = 16.7% and F(66.7) = 33.3%, respec-
tively; p b 0.05] when compared with the vehicle group. Percentages of
number of dead animals decreased signiﬁcantly in CC 50 and CC 75
groups [F(83.3) = 16.7% and F(66.7) = 33.3%, respectively; p b 0.05]
when compared with the vehicle group.
4. Discussion
New treatments to epilepsy should ﬁght a large number of brain in-
sults capable of producing seizures. Literature shows that there is a long
period of time between latency and the insult for the ﬁrst clinical sei-
zure, but our knowledge of the epileptogenic process itself is still limited
(Loeb, 2011). Epilepsy is a common disease and has a negative impact
on the patient's life, whose treatment cannot cure. Investigation of epi-
lepsy development or epileptogenesis has yielded new insights into po-
tential therapies that may prevent epilepsy (Blumenfeld, 2011).
Amongmodels used to study epilepsy, PILOmodel in rodents repro-
duces themain features of mesial temporal lobe epilepsy related to hip-
pocampus sclerosis (MTLE-HS) in humans (Lopes et al., 2013). Costa
et al. (2012a) observed the anticonvulsant and antioxidant effects of
acute treatment with cyane-carvone on pilocarpinemodel, but their re-
sults were not generalizable to other seizure models. Pilocarpine is a
cholinergic drug, and so, even the cyane-carvone can be affecting the
cholinergic system in pilocarpine model. The possible effectiveness of
cyane-carvone in protecting the brain from neurotoxicity that follows
pilocarpine-induced seizures by stimulation of the AChE activity is
described.
In this work, following the administration of PILO in the vehicle
group, mice showed some behavioral changes: piloerection, akinesia,
ataxia, tremor, automatisms and wet-dog shakes. These behavioral
changes were continuous until the installation of seizures, including
clonic movements of the upper extremities, which occurred in 100% of
animals at 7.2 ± 1.1 s after administration of PILO. In the same group,
the seizures progressed to the development of status epilepticus in
100% of the animals and the survival rate was 00%.
Cyane-carvone administration increased installation time ofﬁrst sei-
zure and reduced both the number of animals showing seizures and the
number of dead animals when compared with vehicle. The results sug-
gest that cyane-carvone can present a signiﬁcant anticonvulsant action
in seizure model induced by PILO and are in agreement with a previous
study, probably due to the modulation of the cholinergic system (Costa
et al., 2012).
The induction of epileptic seizures by pentylenetetrazol is other val-
idated model to study epileptic seizures. According to Okoye et al.
(2013), herbal preparations of Annona senegalensis Pers. (Annonaceae)
root bark are used in Nigerian ethnomedicine for epilepsy treatment
and febrile seizures. The researchers found that kaurenoic acid is the ac-
tive constituent that exhibited activity against PTZ-induced seizures in
424 T.H.C. Marques et al. / Pharmacology, Biochemistry and Behavior 124 (2014) 421–424mice. In addition, Ramos et al. (2012) have suggested that the
GABAergic, glutamatergic and adenosinergic systems are involved in
PTZ-induced seizures, as well as alterations in NMDA, kainite, A1 recep-
tors and benzodiazepine binding site densities.
Cyane-carvone protectedmice against PTZ and signiﬁcantly delayed
the onset of myoclonus jerks and tonic seizures. We assessed the CC ef-
fects (25, 50, and 75 mg/kg i.p.) on PTZ-induced generalized seizures in
adult male mice. The results suggest that cyane-carvone can also pres-
ent a signiﬁcant anticonvulsant action in seizure model induced by PTZ.
Flumazenil is a benzodiazepine antagonist (Saxona et al., 2010). The
pretreatment with ﬂumazenil prior to administration of diazepam
blocked the anticonvulsant effect of the benzodiazepine in the PILO
and PTZ-induced seizures tests. However, the benzodiazepine antago-
nist did not block cyane-carvone anticonvulsant effect. Thereat, cyane-
carvone could act either in an allosteric site of GABAA, which would be
different from the site in which BZD acts, or in other neurotransmitter
systems.
Epilepsy is a chronic neurological disorder characterized by recur-
rent seizures. However, approximately one-third of epilepsy patients
still suffer from uncontrolled seizures. Effective treatments for epilepsy
are yet to be developed. N(6)-(3-methoxyl-4-hydroxybenzyl) adenine
riboside is a N(6)-substitued adenosine analog that had a dose-related
anticonvulsant effect in PTX-induced seizuremodel (Li et al., 2013). Ep-
ileptic seizures have been related to both increase in glutamatergic acti-
vation and decrease in GABAergic inhibition (Kesim et al., 2012). It has
been shown that GABAergic and glutamatergic synaptic activity are
very important on epileptic seizures in hippocampal pyramidal CA3
cells, and epileptic seizures are caused by the decrease in the gabaergic
activity (Lasztoczi et al., 2009).
PTX is a speciﬁc GABAA chloride channel blocker (Kesim et al., 2012).
In the PTX-test, cyane-carvone increased installation time of ﬁrst sei-
zure and reduced the number of animals showing seizures and the
number of dead animals when compared to the vehicle group. These re-
sults suggest that cyane-carvone can also present a signiﬁcant anticon-
vulsant action in seizure model induced by PTX.
Fig. 2 shows the possible mechanism of action of cyane-carvone, in-
volving binding site (diferent of BDZ binding site) in GABAA receptor.
5. Conclusion
Acute treatment with cyane-carvone at repeated oral doses for
14 days showed anticonvulsant effect in the PILO, PTZ and PTX models
of induced seizures in mice, noting that cyane-carvone can act either in
an allosteric site of GABAA, which would be different from the site inFig. 2. Possible action mechanism of cyane-carvone in the GABAA receptor.which BZD acts, or in other neurotransmitter systems. Thus, the results
support the knowledge that cyane-carvone can beused, after further re-
search, as a new pharmaceutical formulation and a promising alterna-
tive for epilepsy treatment.
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